Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy ...

Administration of 0.3 or 0.6 mg of liraglutide was well tolerated, however, 1.2 mg of liraglutide induced nausea and vomiting, and decreased the maximum volume nutrients consumed.

January 26, 2010 — Liraglutide injection (Victoza, Novo Nordisk) was approved yesterday by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes in adults.

A metaanalysis of clinical trials using liraglutide shows that it is more effective than other commonly used drugs for reducing blood glucose levels in people with for type 2 diabetes.

The addition of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to metformin with or without basal insulin, improves glycemic control in children and adolescents with type 2 ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

On 23 May 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration (FDA) in the US for the approval of liraglutide for the treatment of people with type 2 diabetes.

Additionally, exendin (a GLP-1R agonist) assays (central and peripheral administration), mRNA central nervous system (CNS) analysis, immunohistochemistry, and fluorescently labeled liraglutide ...

Despite the launch of a genericized version of liraglutide by Teva Pharmaceutical Industries, Ltd. in June of 2024, Novo Nordisk generated US$1.0 billion in Saxenda® revenue, as well as an ...

The cost of Saxenda (liraglutide’s brand name) varies depending on treatment plan, insurance coverage and pharmacy, but according to Novo Nordisk, the monthly list price of the drug is $1,349.02.